RPG Life Sciences Limited (BOM:532983)
India
· Delayed Price · Currency is INR 2,064.10
+92.55 (4.69%)
At close: Apr 11, 2025
RPG Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 6,373 | 5,821 | 5,128 | 4,402 | 3,891 | 3,756 | Upgrade
|
| Revenue Growth (YoY) | 11.12% | 13.50% | 16.50% | 13.11% | 3.61% | 13.75% | Upgrade
|
| Cost of Revenue | 2,115 | 1,893 | 1,758 | 1,469 | 1,356 | 1,320 | Upgrade
|
| Gross Profit | 4,259 | 3,928 | 3,370 | 2,932 | 2,535 | 2,436 | Upgrade
|
| Selling, General & Admin | 1,487 | 1,542 | 1,346 | 1,153 | 1,055 | 992.7 | Upgrade
|
| Other Operating Expenses | 1,223 | 1,104 | 988.4 | 915.5 | 779.5 | 850.4 | Upgrade
|
| Operating Expenses | 2,915 | 2,817 | 2,489 | 2,225 | 1,999 | 2,007 | Upgrade
|
| Operating Income | 1,343 | 1,111 | 881 | 707.4 | 536.6 | 429.5 | Upgrade
|
| Interest Expense | -5.8 | -4.5 | -3.1 | -5.2 | -7.9 | -17.5 | Upgrade
|
| Interest & Investment Income | 14.2 | 14.2 | 27.3 | 13.3 | 3.2 | 1.7 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.1 | 0.1 | 5 | 7.3 | 4 | 4.9 | Upgrade
|
| Other Non Operating Income (Expenses) | 67.8 | 47.2 | 14.4 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 1,420 | 1,168 | 924.6 | 722.8 | 535.9 | 418.6 | Upgrade
|
| Gain (Loss) on Sale of Investments | 10.5 | 10.5 | - | 8.9 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.1 | 0.1 | -7.8 | - | -0.1 | -1.1 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -53.2 | Upgrade
|
| Other Unusual Items | -273 | - | - | - | - | - | Upgrade
|
| Pretax Income | 1,157 | 1,178 | 916.8 | 731.7 | 535.8 | 364.5 | Upgrade
|
| Income Tax Expense | 365.9 | 301.8 | 240.4 | 216.9 | 135.8 | 74.4 | Upgrade
|
| Earnings From Continuing Operations | 791.3 | 876.6 | 676.4 | 514.8 | 400 | 290.1 | Upgrade
|
| Net Income | 791.3 | 876.6 | 676.4 | 514.8 | 400 | 290.1 | Upgrade
|
| Net Income to Common | 791.3 | 876.6 | 676.4 | 514.8 | 400 | 290.1 | Upgrade
|
| Net Income Growth | -6.65% | 29.60% | 31.39% | 28.70% | 37.88% | 168.36% | Upgrade
|
| Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Change (YoY) | 0.01% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 47.84 | 53.00 | 40.90 | 31.13 | 24.19 | 17.54 | Upgrade
|
| EPS (Diluted) | 47.84 | 53.00 | 40.90 | 31.13 | 24.19 | 17.54 | Upgrade
|
| EPS Growth | -6.66% | 29.60% | 31.39% | 28.70% | 37.88% | 168.36% | Upgrade
|
| Free Cash Flow | - | 251.3 | 580.9 | 408 | 497.6 | 394.3 | Upgrade
|
| Free Cash Flow Per Share | - | 15.19 | 35.12 | 24.67 | 30.09 | 23.84 | Upgrade
|
| Dividend Per Share | - | 16.000 | 12.000 | 9.600 | 7.200 | 4.000 | Upgrade
|
| Dividend Growth | - | 33.33% | 25.00% | 33.33% | 80.00% | 66.67% | Upgrade
|
| Gross Margin | 66.82% | 67.48% | 65.72% | 66.62% | 65.15% | 64.87% | Upgrade
|
| Operating Margin | 21.08% | 19.08% | 17.18% | 16.07% | 13.79% | 11.44% | Upgrade
|
| Profit Margin | 12.42% | 15.06% | 13.19% | 11.70% | 10.28% | 7.72% | Upgrade
|
| Free Cash Flow Margin | - | 4.32% | 11.33% | 9.27% | 12.79% | 10.50% | Upgrade
|
| EBITDA | 1,517 | 1,271 | 1,024 | 846.2 | 683.5 | 563.1 | Upgrade
|
| EBITDA Margin | 23.80% | 21.84% | 19.97% | 19.23% | 17.56% | 14.99% | Upgrade
|
| D&A For EBITDA | 173.8 | 160.6 | 143 | 138.8 | 146.9 | 133.6 | Upgrade
|
| EBIT | 1,343 | 1,111 | 881 | 707.4 | 536.6 | 429.5 | Upgrade
|
| EBIT Margin | 21.08% | 19.08% | 17.18% | 16.07% | 13.79% | 11.44% | Upgrade
|
| Effective Tax Rate | 31.62% | 25.61% | 26.22% | 29.64% | 25.35% | 20.41% | Upgrade
|
| Revenue as Reported | 6,466 | 5,893 | 5,176 | 4,432 | 3,901 | 3,763 | Upgrade
|
| Advertising Expenses | - | 213 | 168.1 | 146.6 | 101 | 74.8 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.